Lotze MT - Search Results

1

Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.

Ekeke CN, Russell KL, Joubert K, Bartlett DL, Luketich JD, Soloff AC, Guo ZS, Lotze MT, Dhupar R. Ekeke CN, et al. Among authors: lotze mt. Ann Surg Oncol. 2021 May;28(5):2715-2727. doi: 10.1245/s10434-020-09477-4. Epub 2021 Feb 11. Ann Surg Oncol. 2021. PMID: 33575873 Free PMC article. Review.

2

Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial.

Rubin JT, Lotze MT, Rosenfelder D, Brumfield A, Howells R, Schwartz R, Sylvestri S, Sammon J, Bron K, Orens P, et al. Rubin JT, et al. Among authors: lotze mt. Ann Surg Oncol. 1995 Jul;2(4):351-9. doi: 10.1007/BF02307069. Ann Surg Oncol. 1995. PMID: 7552626 Clinical Trial.

3

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Kalinski P, et al. Among authors: lotze mt. Expert Opin Biol Ther. 2005 Oct;5(10):1303-15. doi: 10.1517/14712598.5.10.1303. Expert Opin Biol Ther. 2005. PMID: 16197336 Review.

4

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. Guo ZS, et al. Among authors: lotze mt. Cancer Res. 2005 Nov 1;65(21):9991-8. doi: 10.1158/0008-5472.CAN-05-1630. Cancer Res. 2005. PMID: 16267024

5

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ 3rd. Popovic PJ, et al. Among authors: lotze mt. J Immunol. 2006 Dec 15;177(12):8701-7. doi: 10.4049/jimmunol.177.12.8701. J Immunol. 2006. PMID: 17142771

6

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Zeh HJ, et al. Among authors: lotze mt. Cancer Biomark. 2005;1(6):259-69. doi: 10.3233/cbm-2005-1601. Cancer Biomark. 2005. PMID: 17192050

7

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. Among authors: lotze mt. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523

8

Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality.

Pan P, Cardinal J, Dhupar R, Rosengart MR, Lotze MT, Geller DA, Billiar TR, Tsung A. Pan P, et al. Among authors: lotze mt. J Leukoc Biol. 2009 Sep;86(3):625-32. doi: 10.1189/JLB.1108713. J Leukoc Biol. 2009. PMID: 19487305

9

Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury.

Cardinal J, Pan P, Dhupar R, Ross M, Nakao A, Lotze M, Billiar T, Geller D, Tsung A. Cardinal J, et al. Hepatology. 2009 Aug;50(2):565-74. doi: 10.1002/hep.23021. Hepatology. 2009. PMID: 19492424

10

Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Guo ZS, et al. Among authors: lotze mt. Am J Cancer Res. 2013;3(1):1-20. Epub 2013 Jan 18. Am J Cancer Res. 2013. PMID: 23359863 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

567 results

Search Page